BioSpring is a German drug substance manufacturing company specializing in oligonucleotide science and technology. BioSpring provides process development, GMP manufacturing, and analytical development services for both clinical and commercial programs, in addition to preclinical material supply and diagnostic manufacturing. The company has produced over 100,000 oligonucleotides in the last 10 years, and provides process validation, product life cycle management, and regulatory support for their clients’ mRNA therapeutics. Headquartered in Frankfurt, Germany, the company also has offices in the United States and Japan.